- Company
- J&J MedTech launches PFA Varipulse platform
- by Whang, byung-woo Apr 3, 2025 05:54am
- Johnson & Johnson MedTech announced on the 1st that it will launch the Varipulse platform, an arrhythmia treatment solution that uses three-dimensional pulsed field ablation (PFA), in Korea. As the most common arrhythmia in the world, Atrial fibrillation (AFib) is a condition in which the atria beat irregularly and rapidly. In particu
- Company
- ‘Leclaza combo will become the sole standard of care’
- by Son, Hyung Min Apr 3, 2025 05:54am
- &160;“The Leclaza + Rybrevant combination therapy has shown a clear improvement in survival compared to Tagrisso monotherapy in the MARIPOSA trial. I am confident that this combination therapy will become the sole standard treatment for EGFR-positive non-small cell lung cancer in the future.” On the 31st, Professor Byoung-chul Cho of t
- Company
- Korea's drug pricing system on US tariff on pharmaceuticals
- by Kim, Jin-Gu Apr 2, 2025 05:56am
- As the Trump administration's tariff against the world will go into effect immediately, a report has been released alleging that Korea's drug pricing and innovative pharmaceutical company certification policies are being unfairly imposed in the United States. According to the KoreaBIO on the 1st, the United States Trade Representative (US
- Company
- Olympus Korea appoints Tamai Takeshi as new head
- by Whang, byung-woo Apr 2, 2025 05:56am
- Olympus Korea, a global medical company, announced on April 1 that it has appointed Tamai Takeshi as its new Representative Director as of April 1. The new Representative Director Takeshi Tamai joined Olympus Korea in 2004 as a marketing manager in the medical business division and served as the General Manager of the medical division in
- Company
- Sanofi launches new dosage form of Praluent with reimb
- by Whang, byung-woo Apr 2, 2025 05:56am
- Sanofi announced on the 1st that a 300 mg dose form of its PCSK9 inhibitor Praluent (alirocumab) will be launched in April with health insurance reimbursement in Korea. According to this announcement, Praluent 300 mg may now be reimbursed when used in patients with primary hypercholesterolemia and mixed dyslipidemia who have been administ
- Company
- 'Rezurock' for cGVHD can be prescribed at 'Big 5' hospitals
- by Eo, Yun-Ho Apr 2, 2025 05:56am
- 'Rezurock,' a treatment for chronic graft-versus-host disease (cGVHD), is now being prescribed in general hospitals. According to industry sources, Sanofi Korea's ROCK2 inhibitor Rezurock (belumosudi) has passed the drug committees (DC) of the 'Big 5' tertiary general hospitals, including Samsung Medical Center, Seoul National University
- Company
- Vaxneuvance's 'immunogenicity' brings competitive edge
- by Whang, byung-woo Apr 2, 2025 05:56am
- With changes in the market for pneumococcal vaccines ahead, MSD Korea has begun to defend its market share by highlighting the “immunogenicity” of Vaxneuvance. Last year, the product was launched and added to the National Immunization Program (NIP), accelerating its market penetration. Celebrating its first year in the NIP, the company
- Company
- What are the remaining issues for Leclaza?
- by Moon, sung-ho Apr 1, 2025 05:53am
- The Leclaza-Rybrevant combination therapy has emerged as the new standard of care for lung cancer treatment and is now being actively implemented in South Korea's clinical settings. As results indicate improvements in progression-free survival (PFS) as well as overall survival (OS) compared to Tagrisso (osimertinib, AstraZeneca), Janssen has
- Company
- Korea is a strategic key R&D site for Boehringer Ingelheim
- by Whang, byung-woo Apr 1, 2025 05:52am
- Boehringer Ingelheim, which has proposed integrated management of cardiovascular-kidney-metabolic syndrome (CRM) with Jardiance at the forefront, has been drawing on innovation through research and development (R&D) investment. Boehringer Ingelheim has already invested more than EUR 5 billion (KRW 7.9666 trillion) in R&D in 2022 globally and
- Company
- Tepmetko granted reimb for METex14+ NSCLC
- by Whang, byung-woo Apr 1, 2025 05:52am
- On the 31st, Merck Korea announced that its Tepmetko (ingredient name: tepotinib), a treatment for MET-ex14 deletion-mutated non-small cell lung cancer, will be reimbursed as of the 1st of next month. Accordingly, Tepmetko is now covered by reimbursement for patients with locally advanced or metastatic non-small cell lung cancer with MET
